Bridgeway Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$283K Buy
44,513
+19,513
+78% +$135K 0.01% 934
2026
Q2
$184K Hold
25,000
– – ﹤0.01% 1074
2026
Q1
$316K Sell
25,000
-15,000
-38% -$172K 0.01% 918
2025
Q4
$411K Hold
40,000
– – 0.01% 861
2025
Q3
$232K Buy
+40,000
New +$234K ﹤0.01% 988

Other funds holding TRDA

Bridgeway Capital Management's TRDA Position: Q3 2026 in Review

Bridgeway Capital Management increased its Entrada Therapeutics (TRDA) stake by 78% in Q3 2026, buying an estimated $135K and bringing the position to 44,513 shares worth $283K. The position accounts for 0.01% of the portfolio, ranked #934.

Bridgeway Capital Management first reported a position in TRDA in Q3 2025 and has held it in 5 quarters since. The position peaked at $411K in Q4 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Bridgeway Capital Management held 44,513 shares of Entrada Therapeutics worth $283K as of Q3 2026.
  • Bridgeway Capital Management bought 19,513 Entrada Therapeutics shares in Q3 2026, an estimated $135K.
  • Entrada Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #934 holding.
  • Bridgeway Capital Management first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Entrada Therapeutics position peaked at $411K in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.